14Nov
13Nov
Carbonite To Be Acquired by OpenText for $1.42 Billion
Data protection and cybersecurity solution provider, Carbonite, has announced it has entered a definitive agreement to be acquired by OpenText. The Enterprise Information Management software and solution provider will acquire Carbonite for $23.00 per share in cash. Read more >>
13Nov
Zylö Receives $225,000 NIH Grant to Further Develop Nitric-Oxide-Releasing Z-pods™ to Treat Erectile Dysfunction
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, has been awarded a $225,000 Small Business Technology Transfer grant. The grant was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (a division of the NIH) to further develop Zylö’s proprietary nitric-oxide topical delivery system (called Z-pods™); and the project is titled, “Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors.” Read more >>
13Nov
100 of the world’s most promising start-ups to watch in 2019
Every year, CNBC scans the globe looking for the 100 venture-backed start-ups that have the potential to transform industries and become tomorrow’s household names. Our 2019 Upstart 100 list showcases young start-ups that are building and scaling businesses addressing the rapidly changing technological era we live in. List includes FutureFuel.io. Read more >>
12Nov
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced continued favorable safety and efficacy outcomes in open-label extensions (OLE) of lenabasum Phase 2 studies in two rare and serious autoimmune diseases: systemic sclerosis (SSc) and dermatomyositis (DM). Read more >>
08Nov
Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment
The study is being conducted in partnership with Zylö Therapeutics to confirm that topical administration of Hoth's AEA-loaded Z-pods™ inhibits the development of CLE lesions in a well-established animal model of lupus. Test protocol requires weekly scoring and a treatment period of 10 weeks after the initial lesions are recorded. Read more >>
07Nov
Dr. Adam Friedman to Present Keynote at Dermatology Fall Update
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that its scientific advisor, Adam Friedman MD, will serve as a keynote speaker at the Dermatology Update 2019 Fall Meeting in Toronto on November 7. Read more >>
06Nov
Regroup Mass Notification Becomes NOAA Weather-Ready Nation Ambassador
Regroup Mass Notification, the award-winning provider of emergency and day-to-day mass communication technology, today announced its official recognition as a Weather-Ready Nation (WRN) Ambassador by the National Oceanic and Atmospheric Administration. Read more >>
06Nov
LaunchPad Medical Wins NIH HEAL Grant to Reduce Opioid Use and Addiction
LaunchPad Medical, Inc. announced that it has received a grant from the National Institutes of Health through its Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, to improve strategies for the prevention and treatment for opioid misuse and addiction.Read more >>
06Nov